--- title: "Invesco Ltd. Buys 14,277 Shares of IDEAYA Biosciences, Inc. $IDYA" description: "Invesco Ltd. increased its stake in IDEAYA Biosciences, Inc. by 25.2% in Q1, acquiring an additional 14,277 shares, bringing its total to 70,968 shares valued at approximately $1.16 million. Other ins" type: "news" locale: "en" url: "https://longbridge.com/en/news/255732961.md" published_at: "2025-09-03T07:38:42.000Z" --- # Invesco Ltd. Buys 14,277 Shares of IDEAYA Biosciences, Inc. $IDYA > Invesco Ltd. increased its stake in IDEAYA Biosciences, Inc. by 25.2% in Q1, acquiring an additional 14,277 shares, bringing its total to 70,968 shares valued at approximately $1.16 million. Other institutional investors also raised their stakes significantly. Analysts have given IDEAYA a consensus rating of "Moderate Buy" with a target price of $47.10. The stock opened at $24.55, with a market cap of $2.15 billion and a recent earnings report showing a loss of $0.88 EPS, missing estimates but exceeding revenue expectations. Invesco Ltd. lifted its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 25.2% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 70,968 shares of the company's stock after buying an additional 14,277 shares during the period. Invesco Ltd. owned approximately 0.08% of IDEAYA Biosciences worth $1,162,000 as of its most recent filing with the Securities and Exchange Commission. Get **IDEAYA Biosciences** alerts: - MarketBeat Week in Review – 7/15 - 7/19 Several other institutional investors have also made changes to their positions in IDYA. CWM LLC boosted its stake in shares of IDEAYA Biosciences by 325.7% in the first quarter. CWM LLC now owns 2,371 shares of the company's stock valued at $39,000 after buying an additional 1,814 shares during the period. PNC Financial Services Group Inc. boosted its stake in shares of IDEAYA Biosciences by 180.2% in the first quarter. PNC Financial Services Group Inc. now owns 2,404 shares of the company's stock valued at $39,000 after buying an additional 1,546 shares during the period. GF Fund Management CO. LTD. bought a new stake in shares of IDEAYA Biosciences in the fourth quarter valued at approximately $47,000. Signaturefd LLC boosted its stake in shares of IDEAYA Biosciences by 374.8% in the first quarter. Signaturefd LLC now owns 2,877 shares of the company's stock valued at $47,000 after buying an additional 2,271 shares during the period. Finally, Exchange Traded Concepts LLC boosted its stake in shares of IDEAYA Biosciences by 46.4% in the first quarter. Exchange Traded Concepts LLC now owns 6,659 shares of the company's stock valued at $109,000 after buying an additional 2,112 shares during the period. 98.29% of the stock is currently owned by institutional investors. ## Analyst Ratings Changes Several research firms have weighed in on IDYA. Wells Fargo & Company began coverage on IDEAYA Biosciences in a research note on Thursday, June 26th. They set an "overweight" rating and a $44.00 target price for the company. JPMorgan Chase & Co. upped their target price on IDEAYA Biosciences from $66.00 to $72.00 and gave the stock an "overweight" rating in a research note on Monday, July 28th. Royal Bank Of Canada upgraded IDEAYA Biosciences from an "outperform" rating to a "moderate buy" rating and cut their target price for the stock from $57.00 to $30.00 in a research note on Wednesday, July 9th. The Goldman Sachs Group upgraded IDEAYA Biosciences to a "hold" rating and set a $25.00 target price for the company in a research note on Thursday, July 10th. Finally, TD Cowen began coverage on IDEAYA Biosciences in a research note on Tuesday, July 22nd. They set a "buy" rating for the company. Nine research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $47.10. - Positive News is Driving This Cancer Drug Maker’s Stock Higher **Get Our Latest Stock Report on IDYA** ## IDEAYA Biosciences Stock Performance Shares of NASDAQ:IDYA opened at $24.55 on Tuesday. The company has a fifty day moving average of $23.33 and a 200-day moving average of $20.49. The company has a market capitalization of $2.15 billion, a PE ratio of -6.48 and a beta of 0.12. IDEAYA Biosciences, Inc. has a 52-week low of $13.45 and a 52-week high of $40.25. IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.03). The firm had revenue of $6.00 million for the quarter, compared to the consensus estimate of $3.48 million. The business's quarterly revenue was up NaN% on a year-over-year basis. During the same period in the previous year, the business earned ($0.68) EPS. On average, equities analysts forecast that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current fiscal year. ## IDEAYA Biosciences Company Profile (Free Report) IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. ## Featured Stories - Five stocks we like better than IDEAYA Biosciences - Upcoming IPO Stock Lockup Period, Explained - 3 Healthcare Pathbreakers With Long-Term Tailwinds - Energy and Oil Stocks Explained - 3 Tariff-Proof Retailers Making New All-time Highs - What is a penny stock? A comprehensive guide - With Shares Near Highs, Here's to Watch in Broadcom's Q3 Report **Want to see what other hedge funds are holding IDYA?** Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report). *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.* ## Should You Invest $1,000 in IDEAYA Biosciences Right Now? Before you consider IDEAYA Biosciences, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEAYA Biosciences wasn't on the list. While IDEAYA Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [IDYA.US - Ideaya Biosciences](https://longbridge.com/en/quote/IDYA.US.md) - [IVZ.US - Invesco](https://longbridge.com/en/quote/IVZ.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Ideaya Biosciences｜10-K：2025 财年营收 2.19 亿美元 | | [Link](https://longbridge.com/en/news/276166957.md) | | 景顺投资管理｜8-K：2025 财年 Q4 营收 16.92 亿美元 | | [Link](https://longbridge.com/en/news/273838507.md) | | 分析 Ideaya Biosciences (IDYA) 在最近财报中净亏损减少后的估值 | IDEAYA Biosciences (IDYA) 在其 2025 财年第四季度和全年业绩中报告了净亏损的减少，当前股价为 30.76 美元。尽管最近上涨了 1.62%，但该股票在过去一个月中已下跌了 14.17%。该公司的市销率为 12. | [Link](https://longbridge.com/en/news/276191881.md) | | IDEAYA Biosciences 第四季度财报：投资者需要知道的事项 | IDEAYA Biosciences（纳斯达克代码：IDYA）于 2026 年 2 月 17 日公布了其第四季度财报，盈利超出预期 4.08%，每股收益（EPS）为-0.94 美元，而预期为-0.98 美元。收入同比增长 388 万美元。在 | [Link](https://longbridge.com/en/news/276117153.md) | | IDEAYA 第四季度的利润略高于预期 | IDEAYA 第四季度的收益略微超出分析师预期，每股收益为-0.94 美元，而市场共识为-0.97 美元。该公司报告的净收入为-8327 万美元，同样超出预期。合作收入同比增长，IDEAYA 预计将在 3 月底之前公布其转移性葡萄膜黑色素瘤 | [Link](https://longbridge.com/en/news/276114938.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.